Navigation Links
Wild vs. lab rodent comparison supports hygiene hypothesis

In a study comparing wild rodents with their laboratory counterparts, researchers at Duke University Medical Center have found evidence that may help to explain why people in industrialized societies that greatly stress hygiene have higher rates of allergy and autoimmune diseases than do people in less developed societies in which hygiene is harder to achieve or considered less critical.

The prevailing hypothesis concerning the development of allergy and probably autoimmune disease is the "hygiene hypothesis," which states that people in "hygienic" societies have higher rates of allergy and perhaps autoimmune disease because they -- and hence their immune systems -- have not been as challenged during everyday life by the host of microbes commonly found in the environment.

The study suggests that an overly hygienic environment could simultaneously increase the tendency to have allergic reactions and the tendency to acquire autoimmune disease, despite the fact that these two reactions represent two different types of immune responses.

The researchers added that their experimental model, which compares specific immune system responses of wild rodents to laboratory rodents, could open up a new approach to studying human disease and allergies that complements traditional scientific studies.

"Laboratory rodents live in a virtually germ- and parasite-free environment, and they receive extensive medical care -- conditions that are comparable to what humans living in Westernized, hygienic societies experience," said William Parker, Ph.D., an assistant professor of experimental surgery and senior member of the study team. "On the other hand, rodents living in the wild are exposed to a wide variety of microbes and parasites, much like humans living in societies without modern health care and where hygiene is harder to maintain."

The researchers published their results early on-line in the Scandinavian Journal of Immunology. The research
'"/>

Source:Duke University Medical Center


Page: 1 2 3 4

Related biology news :

1. Scientists discover odd-ball rodent
2. Longer-lived rodents have lower levels of thyroid hormone
3. Scientists discover new species of distinctive cloud-forest rodent
4. Multi-species genome comparison sheds new light on evolutionary processes, cancer mutations
5. Genomic comparison of lactic acid bacteria published
6. New evidence supports century-old theory of cancer spread
7. Slow-frozen people? Latest research supports possibility of cyropreservation
8. Study supports urgent need for worldwide ban on lead-based paint
9. UWM brain research supports drug development from jellyfish protein
10. Hofmeyr skull supports the Out of Africa theory
11. Strongest proof yet found for prion hypothesis

Post Your Comments:
(Date:11/25/2009)...tate University assistant professors recently rece...(NSF) to continue research beneficial to understan...000. , Christopher Blackwood, assistant professo...arded grants to support two separate research proj...tter Decomposer Communities and Functions from the...
(Date:11/24/2009)...ence is opening new doors to understanding how sou...aring of a marine mammal or if they hear it at al...ay scanners that NASA uses to detect flaws in the ... allowing scientists to peek inside the giant head...e-dimensional replicas of a whale,s hearing anatom...
(Date:11/24/2009)...nd the American College of Medical Toxicology (ACM...publication of the Journal of Medical Toxicology ...g in March 2010. It was previously published by t...rnal of Medical Toxicology , an international, pee...science and practice of medical toxicology. The q...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Rocket science leads to new whale discovery 2Springer and the American College of Medical Toxicology to work together 2Strep B Seems to Trick Immune System 51448 1Bathtub Accidents Injure 43 000 U S Kids Each Year 51446 1Bathtub Accidents Injure 43 000 U S Kids Each Year 51446 2National Trauma Institute Announces 15th Annual Trauma Symposium in San Antonio August 31 September 1 51444 1National Trauma Institute Announces 15th Annual Trauma Symposium in San Antonio August 31 September 1 51444 2
...ered that two microRNA (miRNA) molecules help cont...of B-cell chronic lymphocytic leukemia (B-CLL), th...r findings, published in the December 15 issue of ...ing as powerful regulators of gene expression in c... drug treatment, the investigators say. , In t...
...blem could be eliminated simply by dusting slag on...& Industry, the magazine of the SCI. , In the ...f damage annually. , Researcher David Cowen and...t applying slag to wheat growing in greenhouses ha...orporate the silica and express it as spiky struct...
... of plants to defend themselves by accumulating hi...me insects, and that such adaptation potentially e...ites may in turn evolve to deal with high levels o...zabeth Pilon-Smits of Colorado State University an...rnia, Berkeley, appear in the November 21st issue ...
Other Biology News:Pair of microRNA molecules controls major oncogene in most common leukemia 2New moth variety disarms plants guarded by selenium 2
(Date:11/24/2009)...24 NeurogesX, Inc. (Nasd...n developing and commercializing novel pain manage...no, President and Chief Executive Officer, is sche...Health Care Conference, to be held December 1-2, 2...York. ,, Mr. DiTonno and Stephen Ghiglieri, Ch...
(Date:11/24/2009)...ly approved the Promega PowerPlex 16 HS System for...g DNA records for the National DNA Index System. ...-- The FBI recently approved the Promega PowerPle...cipating in, or generating DNA records for, the Na...tains more than seven million profiles and has ass...
(Date:11/24/2009)...Newswire-FirstCall/ -- Shire plc (LSE: SHP,NASDAQ... company, today,announced that it has submitted a ...rase alfa, the company,s enzyme replacement therap...er disease. This is the third marketing,applicatio...with previous,submissions in the United States and...
(Date:11/24/2009)...r 24 Health Robotics today announc... with a group of selected,investors. This recently...he,name Health Robotics Canada, Inc. and will mark...m of the Future concept, which includes the,revolu...T(TM), and OMM(TM).,Health Robotics Canada Inc. wi...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 3
...12 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) to...e 3 clinical programs, Unit Dose Budesonide (UDB) ... treatment of migraine. For UDB, all,patients hav...itial Phase 3,clinical trial, and for MAP0004, the...in its initial Phase 3 clinical trial by the end o...
...of Schedule , , ST. LOUIS and RICHMOND, Calif., ... ) today announced it has reached a major producti...h Sigma-Aldrich Corporation (Nasdaq: SIAL ) to c...for research applications. The milestone triggers ...ng this production milestone more than one year ah...
...sset, Inc. (Nasdaq: VRUS ) announced today that ...reed with the FDA on the final design for a phase ...atitis C (HCV), slated to initiate in the first qu...8 is advancing into a large phase 2b trial," state...ical Officer. "R7128 is the most advanced nucleosi...
Other Biology Technology:MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 2MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 3Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 2Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 3Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 2Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 5
Rabbit Anti-Mouse SHPRH Polyclonal Antibody, Unconjugated from IMGENEX
Rabbit Anti-PI3K p110 delta (Poly6049) Polyclonal Antibody, Unconjugated from BioLegend
Rabbit Anti-Tyrosine Hydroxylase, phospho (Ser40) Polyclonal Antibody, Unconjugated from IMGENEX
NF kappa B Related Sampler Kit from BD Biosciences Pharmingen
Biology Products: